Guerbet SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Guerbet SA Announces FY 2012 Dividend Proposal
Guerbet SA announced that it will submit a proposal to the general meeting of May 24, 2013 for payment of a dividend of EUR 2 per share for full year 2012, representing a payout ratio of 2.08% based on the share price of 31 December 2012.
Latest Developments for Guerbet SA
- Guerbet SA announces FDA approves Lipiodol (Ethiodized Oil) injection for imaging of tumors in adults
- Guerbet SA proposes FY 2013 dividend and issues FY 2014 financial guidance
- Guerbet launches CE-marked FlowSens solution on global markets
- Guerbet SA receives FDA approval for new manufacturing plant for Lipiodol injection
Latest Key Developments in Pharmaceuticals
- Abbott Laboratories reaffirms FY 2014 EPS outlook
- Emergent BioSolutions Successfully Completes Pivotal Clinical Study
- Synmosa Biopharma to acquire stake in Health Chmical Pharmaceutical
- DBV Technologies announces first reported case of long term sustained effect of peanut desensitization after Epicutaneous Immunotherapy (EPIT) with Viaskin
- Share this
- Digg this